Literature DB >> 19424672

[Optimal therapy of diabetic nephropathy: AVOID Study (Aliskiren in the evaluation of proteinuria in diabetes)].

R E Schmieder1, S Nitschmann.   

Abstract

Entities:  

Year:  2009        PMID： 19424672     DOI： 10.1007/s00108-009-2391-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  3 in total

1.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Authors:  Janice Lea; Tom Greene; Lee Hebert; Michael Lipkowitz; Shaul Massry; John Middleton; Stephen G Rostand; Edgar Miller; Winifred Smith; George L Bakris
Journal:  Arch Intern Med       Date:  2005-04-25

Review 2.  Low-grade albuminuria and cardiovascular risk : what is the evidence?

Authors:  Roland E Schmieder; Joachim Schrader; Walter Zidek; Ulrich Tebbe; W Dieter Paar; Peter Bramlage; D Pittrow; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2007-04-26       Impact factor: 5.460

3.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321
  3 in total
  1 in total

Review 1.  Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits.

Authors:  Giuliano Tocci; Barbara Citoni; Vivianne Presta; Giovanna Leoncini; Francesca Viazzi; Barbara Bonino; Massimo Volpe; Roberto Pontremoli
Journal:  Intern Emerg Med       Date:  2019-12-21       Impact factor: 3.397
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.